Results 21 to 30 of about 7,633 (200)

Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology
The gut microbiome can contribute to drug metabolism and significantly influence pharmacokinetic (PK) behavior. Sulfasalazine is well‐known to be metabolized by gut bacterial azoreductases into sulfapyridine and mesalamine.
Lisa Cheng   +8 more
doaj   +2 more sources

Recurrent pleuropericarditis associated with mesalazine therapy masked by steroid use [PDF]

open access: yesEuropean Journal of Case Reports in Internal Medicine
Introduction: Mesalazine is a cornerstone therapy for ulcerative colitis (UC). Although generally safe, it can cause rare but life-threatening cardiopulmonary complications such as pleuropericarditis.
Hakan Demiröz   +6 more
doaj   +2 more sources

A novel pH–enzyme-dependent mesalamine colon-specific delivery system

open access: yesDrug Design, Development and Therapy, 2016
Lei Jin, Yi-cun Ding, Yu Zhang, Xiao-qing Xu, Qin Cao Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China Abstract: The aim of the present study was to ...
Jin L, Ding Y, Zhang Y, Xu X, Cao Q
doaj   +1 more source

Adjunctive Pentoxifylline Enhances Clinical Remission and Reduces Inflammatory Biomarkers in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-Controlled Pilot Trial [PDF]

open access: yesPharmaceuticals
Background: Despite mesalamine’s efficacy in mild-to-moderate ulcerative colitis (UC), many patients fail to achieve complete clinical or biochemical remission.
Mohannad O. Khrieba   +15 more
doaj   +2 more sources

Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery

open access: yesGels, 2023
This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal   +8 more
doaj   +2 more sources

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

open access: yesClinical and Experimental Gastroenterology, 2009
Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj   +1 more source

Mesalamine-induced myopericarditis - A case report [PDF]

open access: yesRevista Española de Enfermedades Digestivas, 2016
Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine.
Bernardo,Sónia   +2 more
core   +5 more sources

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

open access: yesDrug Design, Development and Therapy, 2011
Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first ...
Lilliana Oliveira, Russell D Cohen
doaj   +2 more sources

Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System [PDF]

open access: yesNanomedicine Research Journal, 2016
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects.
Simin Seifirad   +4 more
doaj   +3 more sources

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine

open access: yesPatient Preference and Adherence, 2009
Daniel B Zandman, Mark A PeppercornHarvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Mesalamine and its derivatives are effective and well-tolerated therapies for ...
Daniel B Zandman, Mark A Peppercorn
doaj   +1 more source

Home - About - Disclaimer - Privacy